Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 750

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 1C
Chunk 750
---
 the Company’s
Trust account, allowing the Company to extend the period of time it has to consummate its initial Business Combination from March 18,
2025 to April 18, 2025.

As
of December 31, 2024, there was $3,537,744 outstanding under the Extension Loans from the Sponsor. As of March 31, 2025, there was $3,650,976
outstanding under the Extension Loans from the Sponsor.

18

Merger
Agreement with Longevity Biomedical Inc.

On
September 16, 2024, the Company, entered into a Merger Agreement”, by and among the Company, Longevity, LBI Merger Sub, Inc., and
Bradford A. Zakes, solely in the capacity as seller representative.

Pursuant
to the Merger Agreement, the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following
the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge
with and into LBI Merger Sub, with Longevity as the surviving entity and becoming a wholly-owned subsidiary of the Company. At the closing
of the Transactions (the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.”
and the Company’s common stock is expected to list on the NASDAQ Capital Market under the ticker symbol “LBIO.”

The
consummation of the proposed Longevity Business Combination is subject to certain conditions as further described in the Merger Agreement.

In
connection with the execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered
into a Voting and Support Agreement (the “Longevity Support Agreement”), pursuant to which the Voting Stockholder has agreed
to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated thereby and (ii) be bound by certain
other covenants and agreements related to the Transactions. The Voting Stockholder holds sufficient shares of Longevity to cause the
approval of the Transactions on behalf of Longevity.

In
connection with the execution of the Merger Agreement, the Company, the Sponsor has entered into a Voting and Support Agreement (the
“Sponsor Support Agreement”). The Sponsor Support Agreement provides that the Sponsor agrees (i) to vote in favor of the
proposed